Parametrica Management’s Royalty Pharma RPRX Stock Holding History

Parametrica Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-8,808	Closed	-$343K	–	288
2022 Q1	$343K	Buy	+8,808	New	+$346K	0.25%	94

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

Parametrica Management's RPRX Position: Q2 2022 in Review

Parametrica Management sold out of Royalty Pharma (RPRX) in Q2 2022, closing a stake of 8,808 shares — an estimated $343K sold.

Parametrica Management first reported a position in RPRX in Q1 2022 and held it in 1 quarter. The position peaked at $343K in Q1 2022. 283 funds tracked by Wall St. Rank hold RPRX as of Q2 2022.

Parametrica Management reported no remaining Royalty Pharma position as of Q2 2022 after selling out during the quarter.
Parametrica Management sold 8,808 Royalty Pharma shares in Q2 2022, an estimated $343K.
Parametrica Management first reported a position in Royalty Pharma in Q1 2022 and held it in 1 quarter.
Parametrica Management's Royalty Pharma position peaked at $343K in Q1 2022.
283 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2022.

Based on Parametrica Management's 13F filing for Q2 2022, filed 22 Jul 2022.